Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy.
Cardiac amyloidosis
Cardiac magnetic resonance imaging
ECV
Feature tracking
GLS
Tafamidis
Transthyretin
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
12 May 2024
12 May 2024
Historique:
revised:
28
02
2024
received:
18
12
2023
accepted:
01
04
2024
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
12
5
2024
Statut:
aheadofprint
Résumé
Tafamidis improves clinical outcomes in transthyretin amyloid cardiomyopathy (ATTR-CM), yet how tafamidis affects cardiac structure and function remains poorly described. This study prospectively analysed the effect of tafamidis on 12-month longitudinal changes in cardiac structure and function by cardiac magnetic resonance (CMR) compared with the natural course of disease in an untreated historic control cohort. ATTR-CM patients underwent CMR at tafamidis initiation and at 12 months. Untreated patients with serial CMRs served as reference to compare biventricular function, global longitudinal strain (GLS), LV mass and extracellular volume fraction (ECV). Thirty-six tafamidis-treated (n = 35; 97.1% male) and 15 untreated patients (n = 14; 93.3% male) with a mean age of 78.3 ± 6.5 and 76.9 ± 6.5, respectively, and comparable baseline characteristics were included. Tafamidis was associated with preserving biventricular function (LVEF (%): 50.5 ± 12 to 50.7 ± 11.5, P = 0.87; RVEF (%): 48.2 ± 10.4 to 48.2 ± 9.4, P = 0.99) and LV-GLS (-9.6 ± 3.2 to -9.9 ± 2.4%; P = 0.595) at 12 months, while a significantly reduced RV-function (50.8 ± 7.3 to 44.2 ± 11.6%, P = 0.028; P (change over time between groups) = 0.032) and numerically worsening LVGLS (-10.9 ± 3.3 to -9.1 ± 2.9%, P = 0.097; P (change over time between groups) = 0.048) was observed without treatment. LV mass significantly declined with tafamidis (184.7 ± 47.7 to 176.5 ± 44.3 g; P = 0.011), yet remained unchanged in untreated patients (163.8 ± 47.5 to 171.2 ± 39.7 g P = 0.356, P (change over time between groups) = 0.027). Irrespective of tafamidis, ECV and native T1-mapping did not change significantly from baseline to 12-month follow-up (P > 0.05). Compared with untreated ATTR-CM patients, initiation of tafamidis preserved CMR-measured biventricular function and reduced LV mass at 12 months. ECV and native T1-mapping did not change significantly comparable to baseline in both groups.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pfizer AG Schweiz
Organisme : GAMBIT Foundation
Organisme : AstraZeneca Schweiz
Organisme : Bern Amyloidosis Registry (B-CARE)
ID : NCT04776824
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Fontana M, Corovic A, Scully P, Moon JC. Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging 2019;12:2345‐2356. doi:10.1016/j.jcmg.2019.06.023
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild‐type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014‐1020. doi:10.1016/j.jacc.2016.06.033
Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV. Global epidemiology of amyloid light‐chain amyloidosis. Orphanet J Rare Dis 2022;17:278. doi:10.1186/s13023‐022‐02414‐6
Lane T, Fontana M, Martinez‐Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 2019;140:16‐26. doi:10.1161/CIRCULATIONAHA.118.038169
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington‐Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007‐1016. doi:10.1056/NEJMoa1805689
Adams D, Gonzalez‐Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11‐21. doi:10.1056/NEJMoa1716153
Huntjens PR, Zhang KW, Soyama Y, Karmpalioti M, Lenihan DJ, Gorcsan J 3rd. Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis. JACC Cardiovasc Imaging 2021;14:1508‐1,519. doi:10.1016/j.jcmg.2021.01.016
Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez‐Naharro A, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging 2019;12:823‐833. doi:10.1016/j.jcmg.2018.02.016
Alwan L, Benz DC, Cuddy SAM, Dobner S, Shiri I, Caobelli F, et al. Current and evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy. JACC Cardiovasc Imaging 2024;17:195‐211. doi:10.1016/j.jcmg.2023.10.010
Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging 2020;13:1368‐1383. doi:10.1016/j.jcmg.2019.07.015
Fontana M, Martinez‐Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR derived extracellular volume with Patisiran indicates cardiac amyloid regression. J Am Coll Cardiol Img 2021;14:189‐199. doi:10.1016/j.jcmg.2020.07.043
Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 2019;12:e006075. doi:10.1161/CIRCHEARTFAILURE.119.006075
Fischer K, Linder OL, Erne SA, Stark AW, Obrist SJ, Bernhard B, et al. Reproducibility and its confounders of CMR feature tracking myocardial strain analysis in patients with suspected myocarditis. Eur Radiol 2022;32:3436‐3446. doi:10.1007/s00330‐021‐08416‐5
Fischer K, Obrist SJ, Erne SA, Stark AW, Marggraf M, Kaneko K, et al. Feature tracking myocardial strain incrementally improves prognostication in myocarditis beyond traditional CMR imaging features. JACC Cardiovasc Imaging 2020;13:1891‐1901. doi:10.1016/j.jcmg.2020.04.025
Treibel TA, Fontana M, Maestrini V, Castelletti S, Rosmini S, Simpson J, et al. Automatic measurement of the myocardial interstitium: synthetic extracellular volume quantification without hematocrit sampling. JACC Cardiovasc Imaging 2016;9:54‐63. doi:10.1016/j.jcmg.2015.11.008
Garg P, Gosling R, Swoboda P, Jones R, Rothman A, Wild JM, et al. Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications. Eur Heart J 2022;43:2511‐2522. doi:10.1093/eurheartj/ehac207
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez‐Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799‐2806. doi:10.1093/eurheartj/ehx589
Shah SJ, Fine N, Garcia‐Pavia P, Klein AL, Fernandes F, Weissman NJ, et al. Effect of Tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR‐ACT randomized clinical trial. JAMA Cardiol 2023; doi:10.1001/jamacardio.2023.4147
Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, et al. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging 2022;23:767‐780. doi:10.1093/ehjci/jeab226
Chamling B, Bietenbeck M, Korthals D, Drakos S, Vehof V, Stalling P, et al. Therapeutic value of tafamidis in patients with wild‐type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging. Clin Res Cardiol 2022;112:353‐362. doi:10.1007/s00392‐022‐02035‐w
Martinez‐Naharro A, Treibel TA, Abdel‐Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol 2017;70:466‐477. doi:10.1016/j.jacc.2017.05.053
Morioka M, Takashio S, Nakashima N, Nishi M, Fujiyama A, Hirakawa K, et al. Correlation between cardiac images, biomarkers, and amyloid load in wild‐type transthyretin amyloid cardiomyopathy. J Am Heart Assoc 2022;11:e024717. doi:10.1161/jaha.121.024717
Garcia‐Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med 2023;389:239‐250. doi:10.1056/NEJMoa2303765